__NUXT_JSONP__("/drugs/Anti-CD33_AntigenCD3_Receptor_Bispecific_Monoclonal_Antibody_AMV564", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"An anti-CD33\u002Fanti-CD3 bispecific tetravalent antibody, with potential immunostimulatory and antineoplastic activities. Anti-CD33\u002FCD3 tetravalent bispecific monoclonal antibody AMV564 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD33, a tumor-associated antigen (TAA) overexpressed on the surface of a variety of tumor cell types. Upon infusion of AMV564, this bispecific antibody binds to CD3-expressing T-cells and CD33-expressing tumor cells, thereby crosslinking CD33-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD33-expressing cells. CD33, a glycoprotein expressed by a variety of cancers, including the majority of acute myeloid leukemias (AMLs), and normal non-pluripotent hematopoietic stem cells, plays a key role in tumor initiation, proliferation and progression.",fdaUniiCode:"56FUB33G5M",identifier:"C135632",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129822","C28227"],synonyms:["AMV 564","AMV-564","AMV564",c,"CD33 x CD3 Tandem Diabody AMV-56","CD33\u002FCD3 TandAbs AMV564"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAnti-CD33_AntigenCD3_Receptor_Bispecific_Monoclonal_Antibody_AMV564",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Anti-CD33_AntigenCD3_Receptor_Bispecific_Monoclonal_Antibody_AMV564","Anti-CD33 Antigen\u002FCD3 Receptor Bispecific Monoclonal Antibody AMV564","2021-10-30T13:31:53.293Z")));